Skip to main content

Serum alanine aminotransferase activity and risk factors for cardiovascular disease in a Caucasian population: the Tromsø study



High and low levels of serum alanine aminotransferase (ALT) are both associated with cardiovascular diseases (CVD) risks especially in elderly, but the mechanisms are less known. This study investigated associations between ALT and CVD risk factors including effects of sex and age in a Caucasian population.


Cross-sectional data were analysed sex-stratified in 2555 men (mean age 60.4 years) and 2858 women (mean age 60.0 years) from the population study Tromsø 6. Associations were assessed by variance analysis and multivariable logistic regression of odds to have abnormal ALT. Risk factors included body mass index (BMI), waist-to-hip-ratio, blood pressure, lipids, glucose, glycated haemoglobin and high-sensitive C-reactive protein (CRP).


Abnormal elevated ALT was detected in 113 men (4.4%) and 188 women (6.6%). Most CVD risk factors associated positively with ALT in both sexes except systolic blood pressure and CRP (women only), while ALT was positively associated with age in men when adjusted for CVD risk factors, P < 0.001. BMI predicted ALT in men (OR 0.94; 95% CI 0.88–1.00, P = 0.047) and women (OR 0.90; 95% CI 0.86–0.95, P < 0.001). A linear inversed association between age and ALT in men and a non-linear inversed U-trend in women with maximum level between 60 and 64 years were found.


This study confirms a positive relationship between ALT and CVD risk factors, particularly BMI. Age is not a major confounder in the ALT-CVD relationship, but separate sex-analyses is recommended in such studies.

Peer Review reports


Elevated levels of alanine aminotransferase (ALT) is associated with higher risk to develop cardiovascular disease (CVD) [1, 2], obesity [3, 4], insulin resistance [5], the metabolic syndrome and type 2 diabetes [6, 7]. The full spectre of underlying mechanisms is unresolved, but ALT-related non-alcoholic fatty liver disease (NAFLD) is an important condition involved, at least in men [8, 9]. Higher prevalence of metabolic abnormalities in men may in part explain sex-differences in associations between ALT and metabolic syndrome [10]. Low levels have also been reported to be unfavourable and may be explained by higher age, sarcopenia and hepatic ageing [11]. Accordingly, a J-shaped ALT-mortality curve is demonstrated [12,13,14]. An American survey with measurement of body composition in 15,028 inhabitants reported higher mortality risk in subgroups with low ALT (deciles 1–3) and an insignificantly increased mortality rate in those with the highest ALT level (decile 10) [14]. The risk excess associated with lower ALT levels was probably due to decreased appendicular lean mass found in the same study fraction [14]. Furthermore, ALT-related coronary disease may be unrelated to presence of risk factors [15, 16]. Whether this may be explained in part by age and sex variations is unknown.

An inversed relationship between age and ALT previously reported [17] has been associated with male sex in particular [4]. Israeli and Italian cohorts of men and women recruited from general practice populations demonstrated an inversed U-shaped relationship between age and ALT [18, 19]. The purposes of the present study were to investigate associations between ALT and CVD risk factors, identify factor(s) most strongly associated with ALT in a Scandinavian predominantly Caucasian general population and clarify the effects of sex and age.


Patients and ethics

The participants of this cross-sectional community study were recruited from the 6th Tromsø Study [20]. ALT was measured in 5413 participants (2555 men and 2858 women), aged 30–87 years, representing 42% of those attended. The ethnic origin included 87.3% Norwegians, 1.6% Sami and 1.3% of Finnish origin, 2.2% of other ethnicities, and 7.6% with unknown ethnicity. The data were collected from October 2007 to September 2008.


Clinical examinations, body mass index (BMI) and blood pressure are performed standardized in the Tromsø study [21]. Self-reported reported previous heart disease was registered via standard questionnaires in the Tromsø study and diabetes defined as glycated haemoglobin (HbA1c) ≥ 6.5%.

ALT, aspartate aminotransferase (AST) and gamma glutamyl transferase (GGT), HbA1c, serum-glucose, total cholesterol, high-density lipoprotein (HDL), low density lipoprotein (LDL) and high-sensitive C-reactive protein (hs-CRP) were analyzed using standard methods at Department of Clinical Biochemistry, University Hospital of North Norway, Tromsø [22]. The standard cut-off limits for ALT, used in the Hospital are those developed by the Nordic Reference Interval Project (NORIP) [23]. Serum ALT reference limits were 10–70 U/L for men and 10–45 U/L in women. Total cholesterol/HDL cholesterol ratio was used in the statistical analyses.

Statistical analysis

ALT values showed left-sided skewness by histograms and therefore log-transformed in the analyses. Additionally, AST, GGT, hs-CRP, HbA1c and glucose-values were log-transformed due to right-sided skewness. Descriptive data are presented as mean and standard deviations (SD) for continuous variables or numbers and frequencies for dichotomous data. Spearman´s correlation coefficient was calculated for associations between continuous variables. Two-sided student´s t-test was used to compare means respectively χ2-test between frequencies of data and ANOVA used to test differences between means of ALT vs. age quartiles and independent variables vs. ALT quartiles while associations between age and ALT adjusted for covariates was done by ANCOVA. By multiple logistic regression analysis, possible confounders were tested and adjusted for with abnormal ALT as dependent variable and age, BMI, waist-to-hip-ratio, diastolic blood pressure, total/HDL cholesterol ratio, triglycerides and log CRP as independent variables; i.e. those variables found statistically significantly associated with ALT in the variance analyses. Systolic blood pressure is not included in the female model due to high correlation with diastolic blood pressure (r = 0.651, P < 0.001). P < 0.05 was considered statistically significant and SPSS software (Statistical Package for Social Science INC, Chicago, Illinois, USA), version 26) was used in the statistical analyses.


Alanine aminotransferase, supplementary blood samples and clinical characteristics in men and women

Table 1 shows characteristics of the subjects in the population. Men had higher levels of liver markers and CVD risk markers including BMI and waist-to-hip-ratio but lower total cholesterol, LDL and HDL levels than women (Table 1). Accordingly, 580 (20.3%) women used lipid lowering drugs compared to 185 (7.2%) in the mail group, P < 0.001. The rate of hypertension was high in the total group, but relatively higher in men (Table 1).

Table 1 Basic characteristics and endpoints of the participants presented as mean (SD) or numbers (%)

Alanine aminotransferase is associated with cardiovascular risk factors

Tables 2 and 3 show positive and significant relationships between ALT and BMI, waist-to-hip-ratio and most CVD-related variables when comparing lowest and highest quartiles of variables. Exceptions are insignificant associations with diastolic blood pressure and CRP in men (Table 2). Thus, CRP-levels were elevated in 1st ALT-quartiles in both sexes and thereby slightly J-shaped. Consequently, the difference between means of ALT in 2 and 4. Quartiles in men was significant (P = 0.03).

Table 2 Age and cardiovascular risk factors in relation to quartiles of log ALT in men (mean and SD or numbers and %)
Table 3 Age and cardiovascular risk factors in relation to quartiles of log ALT in women (mean and SD or numbers and %)

Age- and sex are differently associated with serum alanine aminotransferase levels

Spearman´s correlation coefficient was inversed in the group of 2555 men (r = − 0.231, P < 0.001) and positive in 2858 women (r = 0.124, P < 0.001). A negative linear association between age quintiles and log ALT was found for men and a non-linear inversed U-shaped relationship with maximum level between 60 and 64 years was observed in women in a variance analysis adjusted for covariates. Thus, mean adjusted log ALT in men changed from 1.51 U/L from the youngest group to 1.37 U/L in the oldest (9.3% decline) (P < 0.001). Adjusted log ALT in women: 1.30 (< 45 years), 1.38 (45–59 years), 1.40 (60–64 years), 1.38 (65–70 years) and 1.33 (≥ 70 years).

BMI independently predicted ALT in men and women

Variables included in the multivariate analysis are those significantly associated with log ALT by ANOVA (Tables 2 and 3) except systolic blood pressure in women. BMI was the only predictor independently associated with log ALT in both sexes after adjusting for age, lipids, glucose, HbA1C (%) (men and women) and log CRP in women (Table 4).

Table 4 Multivariable logistic regression of independent variables with odds (OR) of having ALT above upper reference limit in men (> 70 U/L) and women (> 45 U/L)


ALT is associated with metabolic components and clinical CVD risk factors, but BMI was the only one independently associated with ALT in both sexes in a multivariate analysis. The relationship between age and ALT showed an inverted U-wave along quantiles of age-groups in women but was linearly and negative in men. Age did only represent a minor impact on the ALT-CVD connection, but only in men.

The positive relationship between ALT and CVD risk factors was independent of sex but age was a weak predictor of elevated ALT in men. The role of ALT in the pathophysiology of CVD is complex [24, 25]. Likewise, how age and sex act as possible confounders are undetermined. Thus, a recent study by Visaria et al. demonstrated increased overall mortality, including CVD-related mortality, to be associated with lower ALT quartiles in both sexes. However, when adjusted for covariates, an independent relation between ALT and CVD-related mortality remained evident in women but not in men [26]. A linear and inversed relationship between age and ALT in both sexes is reported in cross-sectional and longitudinal studies [17, 27]. An Australian community study in 1673 elderly men (≥ 70 years) designed as a survival analyses, showed an inversed relationship between age and ALT like the findings in the male group here [28]. That study found low ALT to be associated with reduced survival partly due to high age, but the mechanisms is otherwise largely unknown [28]. However, obesity without accompanied CVD has been related to increased survival (the obesity paradox) [29]. Like the present study, age and ALT was negatively correlated in men contrasting the positive relationship in women. Accordingly, the third U.S. National Health and Nutrition Examination Survey (n = 5724) reported positive associations between age and male sex in relation to ALT which abolished in a multivariate analysis. Also, BMI remained significantly associated with ALT [4]. Age, sex and BMI also influenced the transaminase levels in children and adolescents. In girls, ALT declined from infancy until 4 years of age, then increased to peak at 16 years. The same U-form was found for boys although a little delayed [30]. Boys had higher ALT levels than girls, and BMI correlated stronger with ALT in boys [30].

Despite different age-ALT curves between men and women in the present study, the relationships between ALT and CVD risk factors including glucose were approximately the same. In women, an inversed U-form with significant and opposite directed age-ALT correlations on both sides of the 60-year cut-off is demonstrated. A similar pattern with ALT-maximum at 65-year of age was found equal for both sexes in a recent cross-sectional study in 10,000 non-diabetic subjects [11]. By showing a similar trend for age vs. fasting glucose levels, glucose was suggested to entail a joint effect on the ALT levels across ages [11]. The same phenomenon is demonstrated in a study that included subjects living in aged home and participants recruited from three general practices (n = 335). ALT values was distributed along an inversed U-shaped curve with a peak level between 40 and 55 years [19]. In parallel, ALT increased until the third decade in men and the fifth decade in women in a large Italian study where ALT additionally associated positively with BMI, glucose and lipids [18].

The pattern of sex-difference in ALT vs. age in the present study is not shown in previous studies, but the data otherwise do not indicate any certain mechanism. A study in an obese cohort from the same area, showed an association between ALT and the muscular component of body composition in both sexes, but ALT was associated with fat mass in men only [22]. Furthermore, ALT was positively correlated with glucose, glycated haemoglobin and cholesterol in obese women [22]. ALT is higher in men than women but whether this is due to different body composition, sex hormones or confounders is unknown [31, 32]. Thus, ALT predicted prevalent coronary heart disease in men according to an European-American study [33].

Limitations to the study

Although the Tromsø study provides robust data, the evidence of the present cross-sectional study may be questioned by low numbers of cases with abnormal elevated ALT used in the logistic regression analyses. Consequently, the power might have been insufficient in order to detect correct connections between biological variables in that part of the analyses (statistical type 2 error). On the other hand, the low correlation coefficients between ALT and age along with highly significant P-values in both men and women may reflect a large sample size with risk of false positive results. Further, the cross-sectional design makes conclusions about causality impossible. Nevertheless, the data may provide evidence to make hypothesis about sex-differences in ALT functions more specific.


ALT is positively associated with CVD risk factors in both sexes. The data especially confirms an independent and equal association between ALT and BMI. The sex-specific variations in ALT levels seem to be unrelated to CVD-related risk factors and is largely unexplained. How age and sex influence upon the ALT-CVD relationship should be further investigated.

Availability of data and materials

Due to ethical and legal restrictions, the data set is only available upon request to the Tromsø Study. Authors given permission to analyze data are not allowed to make data sets publicly available. Any enquiries should be sent to the Institutional Data Access committee of The Tromsø study, Department of Community Medicine, Faculty of Health Sciences, UiT, The Arctic University of Tromsø (



Alanine aminotransferase


Analysis of covariance


Analysis of variance


Aspartate aminotransferase


Body mass index


Cardiovascular disease


Confidence interval

HbA1C :

Glycated haemoglobin


Gamma glutamyl transferase


High density lipoprotein


High-sensitive C-reactive protein


Low density lipoprotein


Non-alcoholic fatty liver disease


Nordic Reference Interval Project


Observed risk


Regional ethical committee


Standard deviation


  1. 1.

    Yokoyama M, Watanabe T, Otaki Y, Takahashi H, Arimoto T, Shishido T, et al. Association of the aspartate aminotransferase to alanine aminotransferase ratio with BNP level and cardiovascular mortality in the general population: The Yamagata study 10-year follow-up. Dis Markers. 2016;2016:4857917.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191(2):391–6.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Klein M, Iazzettii L, Speiser P, Carey D, Shelov S, Accacha S, et al. Alanine transferase: an independent indicator of adiposity related comorbidity risk in youth. J Diabetes. 2015;7(5):649–56.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124(1):71–9.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Hanley AJ, Wagenknecht LE, Festa A, D’Agostino RB Jr, Haffner SM. Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2007;30(7):1819–27.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(6):1889–95.

    CAS  Article  Google Scholar 

  7. 7.

    Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome: evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–44.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53(4):686–92.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine. 2017;96:17: e6770; doi:

  10. 10.

    Chen KW, Meng FC, Shih YL, Su FY, Lin YP, Lin F, et al. Sex-specific association between metabolic abnormalities and elevated alanine aminotransferase levels in a military cohort: the CHIEF study. Int J Environ Res Public Health. 2018;15:3.

    CAS  Article  Google Scholar 

  11. 11.

    Preuss HG, Kaats GR, Mrvichin N, Bagchi D, Preuss JM. Circulating ALT levels in healthy volunteers over life-span: assessing aging paradox and nutritional implications. J Am Coll Nutr. 2019;38(8):661–9.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Deetman PE, Alkhalaf A, Landman GW, Groenier KH, Kootstra-Ros JE, Navis G, et al. Alanine aminotransferase and mortality in patients with type 2 diabetes (ZODIAC-38). Eur J Clin Invest. 2015;45(8):807–14.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Blokzijl H, Gansevoort RT, Dullaart RP. Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: the PREVEND study. Atherosclerosis. 2015;243(1):138–47.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Ruhl CE, Everhart JE. The association of low serum alanine aminotransferase activity with mortality in the US population. Am J Epidemiol. 2013;178(12):1702–11.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Ndrepepa G, Holdenrieder S, Colleran R, Cassese S, Xhepa E, Fusaro M, et al. Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. Clin Chim Acta. 2019;496:55–61.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Afarideh M, Aryan Z, Ghajar A, Noshad S, Nakhjavani M, Baber U, et al. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. Atherosclerosis. 2016;254:42–51.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Dong MH, Bettencourt R, Barrett-Connor E, Loomba R. Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PloS One. 2010;5:12:e14254; doi:

  18. 18.

    Vespasiani-Gentilucci U, Gallo P, Piccinocchi G, Piccinocchi R, Schena E, Galati G, et al. Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age. Dig Liver Dis. 2014;46(10):909–15.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Elinav E, Ben-Dov IZ, Ackerman E, Kiderman A, Glikberg F, Shapira Y, et al. Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am J Gastroenterol. 2005;100(10):2201–4.

    Article  PubMed  Google Scholar 

  20. 20.

    Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: the Tromso study. Int J Epidemiol. 2012;41(4):961–7.

    Article  PubMed  Google Scholar 

  21. 21.

    Johnsen SH, Lilleng H, Wilsgaard T, Bekkelund SI. Creatine kinase activity and blood pressure in a normal population: the Tromso study. J Hypertens. 2011;29(1):36–42.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Bekkelund SI, Jorde R. Alanine aminotransferase and body composition in obese men and women. Dis Markers. 2019;2019:1695874.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Rustad P, Felding P, Franzson L, Kairisto V, Lahti A, Martensson A, et al. The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest. 2004;64(4):271–84.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):187–201.

    Article  PubMed  Google Scholar 

  25. 25.

    Liu Z, Ning H, Que S, Wang L, Qin X, Peng T. Complex association between alanine aminotransferase activity and mortality in general population: a systematic review and meta-analysis of prospective studies. PloS One. 2014;9:3:e91410; doi:

  26. 26.

    Visaria A, Pai S, Fayngersh A, Kothari N. Association between alanine aminotransferase within the normal range and all-cause and cause-specific mortality: A nationwide cohort study. PloS One. 2020;15:11:e0242431; doi:

  27. 27.

    Dong MH, Bettencourt R, Brenner DA, Barrett-Connor E, Loomba R. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis. Clin Gastroenterol Hepatol. 2012;10(3):285-90.e1.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Le Couteur DG, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010;65(7):712–7.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Myers J, Lata K, Chowdhury S, McAuley P, Jain N, Froelicher V. The obesity paradox and weight loss. Am J Med. 2011;124(10):924–30.

    Article  PubMed  Google Scholar 

  30. 30.

    Bussler S, Vogel M, Pietzner D, Harms K, Buzek T, Penke M, et al. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase): effects of age, sex, body mass index, and pubertal stage. Hepatology. 2017.

    Article  Google Scholar 

  31. 31.

    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1–10.

    CAS  Article  Google Scholar 

  32. 32.

    Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, et al. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PloS One. 2011;6:6:e21178; doi:

  33. 33.

    Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, et al. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 2013;227(2):420–4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references


I am indebted to the Norwegian Institute of Public Health for their participation in the data collection in the sixth survey of the Tromsø Study. The publication charges for this article have been funded by a grant from the publication fund of UiT, The Arctic University of Norway.


Not applicable.

Author information




SIB designed the study, analyzed and interpreted the data, wrote and revised the manuscript. The author read and approved the final manuscript.

Corresponding author

Correspondence to Svein Ivar Bekkelund.

Ethics declarations

Ethics approval and consent to participate

The Tromsø study was approved by the Norwegian Committee for Medical and Health Research Ethics (REC), reference number 121/2006. All participants in The Tromsø Study have given informed written consent.

Consent to publication

Not applicable.

Competing interests

The author declares that there is no conflict of interest related to the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bekkelund, S.I. Serum alanine aminotransferase activity and risk factors for cardiovascular disease in a Caucasian population: the Tromsø study. BMC Cardiovasc Disord 21, 29 (2021).

Download citation


  • Alanine aminotransferase
  • Sex difference
  • Age
  • BMI
  • Population study